Application of urine cfDNA in liquid biopsy research workflows

While initial liquid biopsy research primarily focused on blood-derived tumor biomarkers, such as circulating tumor DNA (ctDNA), recent studies have also identified cancer-derived nucleic acids also in urine. Urinary cell-free DNA (cfDNA) holds great promise, since urine collection is not just a truly non-invasive sample but also has shown to have complementary information to blood.

However, urine cfDNA analysis comes with several challenges, such as loss of target cfDNA due to the high activity of nucleic acid hydrolyzing enzymes, which are 100-fold more active in urine than to plasma. Dilution of target cfDNA is another critical issue, as urine can contain DNA from non-cancerous cells, inflammatory cells, or bacteria. This results in low overall concentrations of cfDNA in urine, which is why urine cfDNA stabilization and the use of highly sensitive detection techniques are required to obtain reliable results. 

We have tested several downstream analyses for urine cfDNA, including digital PCR and next-generation sequencing (NGS) approaches in three cancer types (metastatic prostate cancer, colorectal cancer, and breast cancer) with and without urine stabilization. Under proper preanalytical conditions, urine can provide complementary information about a patient’s tumor that might be missed in plasma. Taken together, particularly in urogenital cancers, the sensitivity of liquid biopsy could be improved by urine cfDNA analyses, provided that standardized preanalytical workflows are used.

The PAXgene Urine Liquid Biopsy Set enables urine cfDNA analysis

Analysis of urine cfDNA can be challenging due to post-collection changes of the urine cfDNA profile. Optimized preanalytical workflows, including urine stabilization, are required for reliable urine cfDNA analysis. In this webinar, we want to introduce the first verified, complete, standardized preanalytical workflow for cell-free DNA (cfDNA) analysis from urine. You will learn about the importance of stabilization, transportation at room temperature, and ease of use using the PAXgene Urine Liquid Biopsy Set. Furthermore, we describe optimized options for automated and manual urine cfDNA isolation from stabilized urine with QIAGEN extraction kits and downstream technologies compatible with the isolated cfDNA. 

In this webinar, learn how QCI Interpret, clinical decision support software for variant interpretation and reporting, can help your lab rapidly identify pathogenic variants, improve diagnostic yields, and significantly reduce test turnaround time for hereditary diseases. Attendees will receive a demonstration of QCI Interpret’s unique capabilities and advanced features for germline variant interpretation with example workflows for carrier screening and whole-exome sequencing panels. Key highlights will include how your lab can expedite variant interpretation by leveraging the most extensive, manually curated knowledge base, dynamically compute pathogenicity based on ACMG guidelines for every variant with full transparency, and leverage QCI Interpret’s proprietary augmented molecular intelligence approach to literature curation and variant classification to streamline your interpretation workflow. 

In this webinar, attendees will: 

• Receive a demonstration of QCI Interpret’s analysis and interpretation workflows for hereditary diseases using targeted and extended gene panels, including whole-genome and whole-exome sequencing. 
• Learn about QIAGEN’s proprietary expert curation process for the knowledge base in QCI Interpret.
• Explore unique time-saving features within QCI Interpret, including phenotype-driven ranking and automation of ACMG guidelines.
• Understand how QCI Interpret supports copy number variant (CNV) interpretation and reporting with bibliographic coverage of over 60,000 CNV case reports.

In this webinar, learn how QCI Interpret, clinical decision support software for variant interpretation and reporting, can help your lab rapidly identify pathogenic variants, improve diagnostic yields, and significantly reduce test turnaround time for hereditary diseases. Attendees will receive a demonstration of QCI Interpret’s unique capabilities and advanced features for germline variant interpretation with example workflows for carrier screening and whole-exome sequencing panels. Key highlights will include how your lab can expedite variant interpretation by leveraging the most extensive, manually curated knowledge base, dynamically compute pathogenicity based on ACMG guidelines for every variant with full transparency, and leverage QCI Interpret’s proprietary augmented molecular intelligence approach to literature curation and variant classification to streamline your interpretation workflow. 

In this webinar, attendees will: 

• Receive a demonstration of QCI Interpret’s analysis and interpretation workflows for hereditary diseases using targeted and extended gene panels, including whole-genome and whole-exome sequencing. 
• Learn about QIAGEN’s proprietary expert curation process for the knowledge base in QCI Interpret.
• Explore unique time-saving features within QCI Interpret, including phenotype-driven ranking and automation of ACMG guidelines.
• Understand how QCI Interpret supports copy number variant (CNV) interpretation and reporting with bibliographic coverage of over 60,000 CNV case reports.

In this webinar, learn how QCI Interpret, clinical decision support software for variant interpretation and reporting, can help your lab rapidly identify pathogenic variants, improve diagnostic yields, and significantly reduce test turnaround time for hereditary diseases. Attendees will receive a demonstration of QCI Interpret’s unique capabilities and advanced features for germline variant interpretation with example workflows for carrier screening and whole-exome sequencing panels. Key highlights will include how your lab can expedite variant interpretation by leveraging the most extensive, manually curated knowledge base, dynamically compute pathogenicity based on ACMG guidelines for every variant with full transparency, and leverage QCI Interpret’s proprietary augmented molecular intelligence approach to literature curation and variant classification to streamline your interpretation workflow. 

In this webinar, attendees will: 

• Receive a demonstration of QCI Interpret’s analysis and interpretation workflows for hereditary diseases using targeted and extended gene panels, including whole-genome and whole-exome sequencing. 
• Learn about QIAGEN’s proprietary expert curation process for the knowledge base in QCI Interpret.
• Explore unique time-saving features within QCI Interpret, including phenotype-driven ranking and automation of ACMG guidelines.
• Understand how QCI Interpret supports copy number variant (CNV) interpretation and reporting with bibliographic coverage of over 60,000 CNV case reports.

In this webinar, learn how QCI Interpret, clinical decision support software for variant interpretation and reporting, can help your lab rapidly identify pathogenic variants, improve diagnostic yields, and significantly reduce test turnaround time for hereditary diseases. Attendees will receive a demonstration of QCI Interpret’s unique capabilities and advanced features for germline variant interpretation with example workflows for carrier screening and whole-exome sequencing panels. Key highlights will include how your lab can expedite variant interpretation by leveraging the most extensive, manually curated knowledge base, dynamically compute pathogenicity based on ACMG guidelines for every variant with full transparency, and leverage QCI Interpret’s proprietary augmented molecular intelligence approach to literature curation and variant classification to streamline your interpretation workflow. 

In this webinar, attendees will: 

• Receive a demonstration of QCI Interpret’s analysis and interpretation workflows for hereditary diseases using targeted and extended gene panels, including whole-genome and whole-exome sequencing. 
• Learn about QIAGEN’s proprietary expert curation process for the knowledge base in QCI Interpret.
• Explore unique time-saving features within QCI Interpret, including phenotype-driven ranking and automation of ACMG guidelines.
• Understand how QCI Interpret supports copy number variant (CNV) interpretation and reporting with bibliographic coverage of over 60,000 CNV case reports.

Time is precious, and so are your samples. Automating the nucleic acid isolations in your human microbiome research can minimize bias while freeing up your lab group's hands (and brains) for more important work. From versatile robots to high throughput machines to affordable instruments, automation is suited for every type of lab. Join our speakers as they explore the different instruments available to automate nucleic acid isolations for human microbiome research. See how these instruments can help reduce bias, increasing the consistency and reliability of your isolations. Our speakers will also review automation best practices and explain which instruments are the most suited for your laboratory and work style.

Time is precious, and so are your samples. Automating the nucleic acid isolations in your human microbiome research can minimize bias while freeing up your lab group's hands (and brains) for more important work. From versatile robots to high throughput machines to affordable instruments, automation is suited for every type of lab. Join our speakers as they explore the different instruments available to automate nucleic acid isolations for human microbiome research. See how these instruments can help reduce bias, increasing the consistency and reliability of your isolations. Our speakers will also review automation best practices and explain which instruments are the most suited for your laboratory and work style.

Time is precious, and so are your samples. Automating the nucleic acid isolations in your human microbiome research can minimize bias while freeing up your lab group's hands (and brains) for more important work. From versatile robots to high throughput machines to affordable instruments, automation is suited for every type of lab. Join our speakers as they explore the different instruments available to automate nucleic acid isolations for human microbiome research. See how these instruments can help reduce bias, increasing the consistency and reliability of your isolations. Our speakers will also review automation best practices and explain which instruments are the most suited for your laboratory and work style.